Severe fever with thrombocytopenia syndrome (SFTS) is an infectious disease caused by a
tick-borne virus called severe fever with thrombocytopenia syndrome virus (SFTSV). In
recent years, human infections through contact with ticks and through contact with the
bodily fluids of infected dogs and cats have been reported; however, no vaccine is
currently available. SFTSV has two glycoproteins (Gn and Gc) on its envelope, which are
vaccine-target antigens involved in immunogenicity. In the present study, we constructed
novel SFTS vaccine candidates using an adeno-associated virus (AAV) vector to transport
the SFTSV glycoprotein genome. AAV vectors are widely used in gene therapy and their
safety has been confirmed in clinical trials. Recently, AAV vectors have been used to
develop influenza and SARS-CoV-2 vaccines. Two types of vaccines (AAV9-SFTSV Gn and
AAV9-SFTSV Gc) carrying SFTSV Gn and Gc genes were produced. The expression of Gn and Gc
proteins in HEK293T cells was confirmed by infection with vaccines. These vaccines were
inoculated into mice, and the collected sera produced anti-SFTS antibodies. Furthermore,
sera from AAV9-SFTSV Gn infected mice showed a potent neutralizing ability, similar to
previously reported SFTS vaccine candidates that protected animals from SFTSV infection.
These findings suggest that this vaccine is a promising candidate for a new SFTS
vaccine.